Janssen Global Services

Halozyme Therapeutics is a biotechnology company that develops and commercializes innovative therapies, particularly in oncology and drug delivery. The company utilizes its proprietary ENHANZE technology, which is based on a recombinant human hyaluronidase enzyme, to facilitate subcutaneous delivery of biologics, improving the absorption and dispersion of injectable therapeutics. Its product portfolio includes Hylenex, designed for fluid administration and enhancing drug absorption, along with various development candidates targeting significant medical needs in cancer and immunodeficiency disorders. Notable therapies being developed include those for breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and other conditions. Halozyme has established collaborations with major pharmaceutical companies, leveraging its technology to enhance therapeutic efficacy. Founded in 1998 and headquartered in San Diego, California, the company aims to address unmet medical needs through its innovative therapeutic approaches and partnerships.

BeneVir's immunotherapies for cancer are designed to induce the immune system to rid the body of two types of tumor cells: those currently responsible for cancer and those responsible for tumor recurrence and poor clinical outcomes. This is a unique approach in the emerging field of cancer immunotherapy.

XO1 Ltd is a biotechnology companied formed specifically to develop ichorcumab. It is a virtual company, with no offices or laboratory space, and operates by engaging high quality contract research and development specialists in Europe and the US, managed by a small team of experienced drug developers. Properly managed, virtual drug development not only controls costs but maximizes quality through flexible selection of the most appropriate supplier for each individual task. Read more: XO1 Ltd raises $11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs - FierceBiotech http://www.fiercebiotech.com/press-releases/xo1-ltd-raises-11-million-index-ventures-develop-holy-grail-anticoagulant-d#ixzz2WSG7D0Bu Subscribe at FierceBiotech

Quanticare Technologies specializes in healthcare technology aimed at enhancing the safety and well-being of seniors. The company has developed an innovative sensor system for walking frames that helps prevent falls, a significant concern for older adults. Additionally, Quanticare's platform allows users to monitor and track their health conditions proactively. By enabling patients to collect and analyze their health data, the technology facilitates early intervention by healthcare practitioners, allowing for timely responses to potential health issues. This dual focus on fall prevention and proactive health monitoring positions Quanticare as a key player in improving the quality of life for seniors.

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.

Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.

Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.

Vertex Pharmaceuticals is a biotechnology company dedicated to the discovery and development of small-molecule drugs aimed at treating serious diseases. The company's primary focus is on areas such as viral diseases, cystic fibrosis, inflammation, autoimmune disorders, cancer, and pain management. Vertex is known for its key cystic fibrosis therapies, including Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, which are considered the standard of care worldwide. Additionally, the company has expanded its portfolio to include Casgevy, a gene-editing therapy for beta thalassemia and sickle cell disease. Vertex is also exploring innovative treatments, such as small-molecule inhibitors for acute and chronic pain that are non-opioid, as well as potential therapies targeting kidney diseases related to APOL1. Through its collaborative and independent commercialization strategies, Vertex aims to bring effective solutions to the market for patients with serious health conditions.

Centocor is an integrated biopharmaceutical company developing monoclonal antibody-based products for cardiovascular and autoimmune diseases, cancer and inflammation.